X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1632) 1632
ceftazidime (1183) 1183
male (956) 956
female (947) 947
index medicus (743) 743
ceftazidime - administration & dosage (709) 709
adult (658) 658
middle aged (620) 620
pharmacology & pharmacy (598) 598
ceftazidime - therapeutic use (534) 534
anti-bacterial agents - administration & dosage (530) 530
antibiotics (513) 513
microbiology (513) 513
aged (507) 507
infectious diseases (482) 482
anti-bacterial agents - therapeutic use (478) 478
adolescent (356) 356
microbial sensitivity tests (348) 348
infections (326) 326
treatment outcome (315) 315
animals (286) 286
pharmacokinetics (286) 286
drug therapy, combination (269) 269
anti-bacterial agents - pharmacology (268) 268
child (246) 246
cephalosporins - administration & dosage (244) 244
bacterial infections - drug therapy (234) 234
infusions, intravenous (231) 231
pseudomonas infections - drug therapy (228) 228
prospective studies (225) 225
ceftazidime - pharmacokinetics (220) 220
ceftazidime - pharmacology (218) 218
anti-bacterial agents - pharmacokinetics (214) 214
aged, 80 and over (207) 207
cephalosporins - therapeutic use (202) 202
pseudomonas-aeruginosa (196) 196
pseudomonas aeruginosa - drug effects (183) 183
therapy (180) 180
pseudomonas aeruginosa (177) 177
child, preschool (174) 174
injections, intravenous (170) 170
cefepime (168) 168
bacteria (167) 167
drug administration schedule (166) 166
meropenem (165) 165
drug therapy (161) 161
antimicrobial agents (158) 158
fever (150) 150
health aspects (150) 150
pediatrics (149) 149
dosage and administration (148) 148
oncology (146) 146
ciprofloxacin (144) 144
research (143) 143
ceftazidime - adverse effects (142) 142
pneumonia (142) 142
infection (141) 141
drug resistance (140) 140
risk factors (139) 139
retrospective studies (137) 137
infant (133) 133
mortality (132) 132
care and treatment (131) 131
vancomycin (129) 129
cephalosporins (123) 123
pharmacodynamics (123) 123
fever - drug therapy (122) 122
cephalosporins - pharmacokinetics (120) 120
research article (120) 120
amikacin (119) 119
neutropenia - drug therapy (119) 119
immunology (117) 117
gram-negative bacteria (114) 114
imipenem (114) 114
resistance (113) 113
gram-negative bacterial infections - drug therapy (112) 112
medicine, general & internal (112) 112
time factors (111) 111
gentamicin (106) 106
children (104) 104
pathogens (104) 104
anti-bacterial agents - adverse effects (103) 103
drug therapy, combination - therapeutic use (103) 103
neutropenia - complications (102) 102
bacteremia (100) 100
ophthalmology (100) 100
analysis (98) 98
ceftazidime-avibactam (98) 98
drug resistance in microorganisms (98) 98
efficacy (98) 98
patients (98) 98
cystic fibrosis (97) 97
drug combinations (97) 97
pharmacology (97) 97
epidemiology (96) 96
ceftazidime - blood (95) 95
dose-response relationship, drug (95) 95
pseudomonas infections - microbiology (94) 94
cancer (93) 93
internal medicine (92) 92
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2131) 2131
Japanese (70) 70
French (42) 42
German (18) 18
Spanish (14) 14
Italian (13) 13
Russian (11) 11
Chinese (9) 9
Polish (4) 4
Dutch (2) 2
Turkish (2) 2
Arabic (1) 1
Czech (1) 1
Danish (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD008319
Background Cystic fibrosis is a genetic disorder in which abnormal mucus in the lungs is associated with susceptibility to persistent infection. Pulmonary... 
Respiratory infections in general | Injections, Intravenous | Lungs & airways | Amikacin | Ticarcillin | TREATMENT | Respiratory infections: general treatment | Forced Expiratory Volume | Infectious disease | Carbenicillin | Child health | Fibrosis: cystic fibrosis | Pseudomonas aeruginosa | PULMONARY INFECTION | ACUTE THERAPY (PULMONARY EXACERBATIONS) | Ceftazidime | Genetic disorders | Cystic Fibrosis | Administration, Inhalation | Cystic fibrosis: antibiotics | Respiratory Tract Infections | Disease Progression | Randomized Controlled Trials as Topic | Antibiotics | Anti‐Bacterial Agents | Respiratory infections | Pseudomonas Infections | Tobramycin | Medicine General & Introductory Medical Sciences | Carbenicillin [administration & dosage] | Tobramycin [administration & dosage] | Humans | Pseudomonas Infections [drug therapy] | Ceftazidime [administration & dosage] | MEDICINE, GENERAL & INTERNAL | Cystic Fibrosis [complications; microbiology] | PSEUDOMONAS-AERUGINOSA INFECTION | SPUTUM TOBRAMYCIN | BRONCHIAL CONSTRICTION | Ticarcillin [administration & dosage] | Respiratory Tract Infections [drug therapy; microbiology] | CF PATIENTS | LUNG-FUNCTION | RESPIRATORY EXACERBATIONS | AEROSOLIZED TOBRAMYCIN | NEBULIZED TOBRAMYCIN | DOUBLE-BLIND | Anti-Bacterial Agents [administration & dosage] | Amikacin [administration & dosage] | AZTREONAM LYSINE | Ticarcillin - administration & dosage | Cystic Fibrosis - microbiology | Pseudomonas Infections - drug therapy | Tobramycin - administration & dosage | Respiratory Tract Infections - drug therapy | Cystic Fibrosis - complications | Respiratory Tract Infections - microbiology | Amikacin - administration & dosage | Ceftazidime - administration & dosage | Carbenicillin - administration & dosage | Anti-Bacterial Agents - administration & dosage
Journal Article
BMC Nephrology, ISSN 1471-2369, 10/2015, Volume 16, Issue 1, p. 158
Background: Dose adjustment for certain drugs is required in patients with reduced renal function to avoid toxicity as many drugs are eliminated by the... 
Prospective | Dose adjustment | Renal impairment | MEDICATION DOSING ERRORS | DIET | DISEASE | UROLOGY & NEPHROLOGY | Prospective Studies | Spironolactone - administration & dosage | Humans | Middle Aged | Fluconazole - administration & dosage | Antihypertensive Agents - administration & dosage | Male | Young Adult | Drug Dosage Calculations | Aged, 80 and over | Adult | Female | Cimetidine - administration & dosage | Enalapril - administration & dosage | Pharmaceutical Preparations - administration & dosage | Medication Errors | Severity of Illness Index | Diuretics - administration & dosage | Vancomycin - administration & dosage | Cross-Sectional Studies | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Hospitalization | Acute Kidney Injury - physiopathology | Anti-Arrhythmia Agents - administration & dosage | Creatinine - urine | Renal Insufficiency, Chronic - physiopathology | Anti-Ulcer Agents - administration & dosage | Gout Suppressants - administration & dosage | Drug Prescriptions - statistics & numerical data | Allopurinol - administration & dosage | Digoxin - administration & dosage | Adolescent | Ceftazidime - administration & dosage | Creatinine - blood | Aged | Anti-Bacterial Agents - administration & dosage | Antifungal Agents - administration & dosage | Ethiopia | Drugs | Prescribing | Medical research | Hospital patients | Prescription writing | Analysis | Medicine, Experimental | Medical care | Quality management
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2016, Volume 62, Issue 11, pp. 1380 - 1389
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 02/2018, Volume 319, Issue 8, pp. 788 - 799
Journal Article
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2016, Volume 63, Issue 6, pp. 754 - 762
Journal Article
Chest, ISSN 0012-3692, 05/2003, Volume 123, Issue 5, pp. 1495 - 1502
Journal Article
Current medical research and opinion, ISSN 1473-4877, 2012, Volume 28, Issue 12, pp. 1921 - 1931
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 12/2016, Volume 2016, Issue 12, p. CD002007
...; advantages of monotherapy include lower cost, ease of administration and reduction of drug... 
Injections, Intravenous | Genetic disorders | Lungs & airways | Cystic Fibrosis | Cystic fibrosis: antibiotics | Aminoglycosides | beta‐Lactams | TREATMENT | Respiratory Tract Infections | Randomized Controlled Trials as Topic | Cephalosporins | Antibiotics | Bacterial Infections | Anti‐Bacterial Agents | Child health | Fibrosis: cystic fibrosis | Pseudomonas aeruginosa | Pseudomonas Infections | Drug Therapy, Combination | Medicine General & Introductory Medical Sciences | PULMONARY INFECTION | ACUTE THERAPY (PULMONARY EXACERBATIONS) | CONTROLLED-TRIAL | ADULT PATIENTS | CEFTAZIDIME MONOTHERAPY | Cephalosporins [administration & dosage] | AERUGINOSA INFECTION | Humans | Cystic Fibrosis [complications] | TICARCILLIN | ONCE-DAILY TOBRAMYCIN | PIPERACILLIN PLUS TOBRAMYCIN | beta-Lactams [administration & dosage] | ACUTE PULMONARY EXACERBATIONS | BETA-LACTAM | MEDICINE, GENERAL & INTERNAL | Aminoglycosides [administration & dosage] | Drug Therapy, Combination [methods] | Anti-Bacterial Agents [administration & dosage] | Bacterial Infections [drug therapy] | Respiratory Tract Infections [drug therapy] | ACUTE RESPIRATORY EXACERBATIONS | Bacterial Infections - drug therapy | Pseudomonas Infections - drug therapy | Respiratory Tract Infections - drug therapy | Cephalosporins - administration & dosage | Cystic Fibrosis - complications | Drug Therapy, Combination - methods | Aminoglycosides - administration & dosage | Anti-Bacterial Agents - administration & dosage | beta-Lactams - administration & dosage
Journal Article